Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa

(2022) Laura Corbella et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory

(2021) Shazad Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy

(2021) Isabel Barceló et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections

(2021) Alba Ruedas-López et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones

(2021) María A. Gomis-Font et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa

(2020) Antonio Vena et al.   CLINICAL INFECTIOUS DISEASES

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

(2020) Mercedes Delgado-Valverde et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

(2020) Jorge Arca-Suárez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria

(2020) Shazad Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

(2020) Jorge Arca-Suárez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone

(2019) Jorge Arca-Suárez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants

(2019) Pablo Fraile-Ribot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

(2019) Jodie C. Hamrick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone

(2017) Carla López-Causapé et al.   Scientific Reports

The increasing threat of Pseudomonas aeruginosa high-risk clones

(2015) Antonio Oliver et al.   DRUG RESISTANCE UPDATES

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology

(2015) Anaïs Potron et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS